Evaluation of Paclitaxel as a Non-Cross-Resistant Agent in Cisplatin-Resistant Small Cell Lung Cancer (SCLC). (2025). International Cancer Research Journal, 1(1), 2. https://doi.org/10.70844/icrj.2025.1.2